Sign In
Buy OPK
$1.46
+0.0600 (+4.29%)
At Close: Jun 03, 2026
OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
07:52pm, Wednesday, 30'th Apr 2025
OPKO Health, Inc. (NASDAQ:OPK ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerh
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say
07:35pm, Wednesday, 30'th Apr 2025
The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates
06:55pm, Wednesday, 30'th Apr 2025
OPKO Health (OPK) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.12 per share a year ago.
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround
10:36am, Tuesday, 22'nd Apr 2025
OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
08:00am, Friday, 04'th Apr 2025
MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
10:36am, Friday, 28'th Mar 2025
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
OPKO and Entera partner to develop obesity pill
08:57am, Monday, 17'th Mar 2025
OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other disorders, the companies said on Monday.
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
11:05am, Friday, 14'th Mar 2025
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp�
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
12:25pm, Friday, 28'th Feb 2025
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
08:00pm, Thursday, 27'th Feb 2025
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics com
OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates
07:50pm, Thursday, 27'th Feb 2025
OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.
OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript
07:12pm, Thursday, 27'th Feb 2025
OPKO Health, Inc. (NASDAQ:OPK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Z
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
04:10pm, Thursday, 27'th Feb 2025
MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the four
Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:20am, Tuesday, 25'th Feb 2025
Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr
